Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Angiotensin-converting enzyme (ACE) inhibitor therapy is established to reduce cardiovascular events in high-risk populations.
• Previous studies indicate ACE inhibitors decrease risks of cardiovascular death, myocardial infarction, stroke, heart failure hospitalizations, and revascularization.
• In patients with heart failure or left ventricular systolic dysfunction, ACE inhibitors also reduce sudden cardiac death risk.

Purpose of the Study:

• To evaluate the efficacy of ramipril in preventing sudden unexpected death or resuscitated cardiac arrest.
• To assess ramipril's impact on arrhythmic events in patients without clinical heart failure or left ventricular dysfunction.
• To analyze outcomes within the Heart Outcomes Prevention Evaluation (HOPE) trial population.

Main Methods:

• A randomized, placebo-controlled trial involving 9297 participants.
• Participants were high-risk individuals without clinical heart failure or overt left ventricular dysfunction.
• Median follow-up duration was 4.5 years.

Main Results:

• Ramipril therapy resulted in a 21% reduction in the composite outcome of unexpected death, arrhythmic death, or resuscitated cardiac arrest (RR 0.79, P=0.028).
• The composite outcome occurred in 3.3% of patients on ramipril versus 4.2% on placebo.
• Trends suggested reductions in fatal primary outcomes (RR 0.81, P=0.072) and nonfatal primary outcomes (RR 0.65, P=0.127) with ramipril.

Conclusions:

• Ramipril effectively reduces the risk of serious fatal and nonfatal arrhythmic events.
• This benefit was observed in high-risk individuals without overt signs of heart failure or left ventricular systolic dysfunction.
• Ramipril demonstrates a protective role against sudden cardiac death in this specific patient cohort.